Cattaneo A G, Caviezel F, Pozza G
Chair of Clinical Medicine, Istituto Scientifico S. Raffaele, Milano, Italy.
Int J Clin Pharmacol Ther Toxicol. 1990 Jun;28(6):229-34.
This study has been planned to investigate some aspects of the interaction between acetylsalicylic acid (ASA) and tolbutamide on insulin secretion. In healthy subjects, oral administration of 3.2 g daily of ASA for 3 days significantly enhanced a) basal insulin levels (p less than 0.01), b) arginine-stimulated insulin secretion (25 g i.v. over 30 min) (p less than 0.01) and c) tolbutamide-stimulated insulin secretion (1 g or 0.25 g i.v. as a bolus) (areas under curves: p less than 0.02). Corresponding decreases in glycemia were observed. Tolbutamide binding to serum proteins was significantly reduced after ASA treatment (p less than 0.02). We conclude that, in case of tolbutamide test, interferences between ASA and tolbutamide on insulin secretion might be dependent, at least in part, on enhancement of free-tolbutamide percentage in plasma and not only on a direct or synergic action of ASA on pancreatic B-cell. Therefore, acute stimulation of insulin secretion by tolbutamide appears not to be completely comparable to other traditional stimuli, when ASA effects are studied.
本研究旨在调查乙酰水杨酸(ASA)与甲苯磺丁脲相互作用对胰岛素分泌影响的某些方面。在健康受试者中,连续3天每天口服3.2 g ASA可显著提高:a)基础胰岛素水平(p<0.01),b)精氨酸刺激的胰岛素分泌(静脉注射25 g,持续30分钟)(p<0.01)以及c)甲苯磺丁脲刺激的胰岛素分泌(静脉推注1 g或0.25 g)(曲线下面积:p<0.02)。同时观察到血糖相应下降。ASA治疗后,甲苯磺丁脲与血清蛋白的结合显著减少(p<0.02)。我们得出结论,在甲苯磺丁脲试验中,ASA与甲苯磺丁脲对胰岛素分泌的干扰可能至少部分取决于血浆中游离甲苯磺丁脲百分比的增加,而不仅仅取决于ASA对胰腺β细胞的直接或协同作用。因此,在研究ASA的作用时,甲苯磺丁脲对胰岛素分泌的急性刺激似乎与其他传统刺激并不完全可比。